The mechanisms of delayed onset type adverse reactions to oseltamivir

References

• CDC. Updated Interim Recommendations for the Use of Antiviral Medications in the Treatment and Prevention of Influenza for the 2009–2010 [Internet]; [cited 2016 Mar 23]. Available from: http://www.cdc.gov/h1n1flu/recommendations.htm
   Google Scholar
• CDC. Influenza antiviral medications: summary for clinicians, (last updated Feb 25 2015) [Internet]; [cited 2016 Mar 23]. Available from: http://www.cdc.gov/flu/professionals/antivirals/summary-clinicians.htm#modalIdString_CDCTable_1.
   Google Scholar
• World Health Organization. WHO Model List of Essential Medicines.19th edition (May 2015) [Internet]; [cited 2016-03-23]. Available from: http://www.who.int/medicines/publications/essentialmedicines/EML2015_8-May-15.pdf?ua =1.
   Google Scholar
• Maxwell SR. Tamiflu and neuropsychiatric disturbance in adolescents. BMJ. 2007;334:1232–1233.
   PubMed Web of Science ®Google Scholar
• Hama R. Discussion of the causal relationship between oseltamivir phosphate (Tamiflu), and sudden death and death from abnormal behavior. Paper presented at the session of Japanese Society for Pediatric Infectious Diseases in Tsu, Mie Prefecture (held on 2005-11-12) [Internet]; [cited 2016 Mar 23]. Available from: http://www.npojip.org/english/no59.html.
   Google Scholar
• Hama R. Fatal neuropsychiatric adverse reactions to oseltamivir: case series and overview of causal relationships. Intern J Risk Safety Med. 2008;20:5–36.
   Google Scholar
• Hama R. Oseltamivir's adverse reactions: fifty sudden deaths may be related to central suppression. BMJ. 2007;335:59
   PubMed Web of Science ®Google Scholar
• Hama R, Jones M, Hayashi K, et al. Oseltamivir and early deterioration leading to death: a proportional mortality study for 2009A/H1N1 influenza. Int J Risk Saf Med. 2011;23:201–215.
   PubMedGoogle Scholar
• Jefferson T, Jones MA, Doshi P, et al. Neuraminidase inhibitors for preventing and treating influenza in healthy adults and children. Cochrane Database Syst Rev. 2014;4:CD008965.
   PubMed Web of Science ®Google Scholar
• Jefferson T, Jones MA, Doshi P, et al. Neuraminidase inhibitors for preventing and treating influenza in healthy adults and children. Cochrane Database Syst Rev. 2012;1:CD008965.
   PubMedGoogle Scholar
• Kohno S, Yen MY, Cheong HJ, et al. (S-021812 Clinical Study Group), et al. Phase III randomized, double-blind study comparing single-dose intravenous peramivir with oral oseltamivir in patients with seasonal influenza virus infection. Antimicrob Agents Chemother. 2011;55:5267–5276.
   PubMed Web of Science ®Google Scholar
• Sugaya N, Ohashi Y. Long-acting neuraminidase inhibitor laninamivir octanoate (CS-8958) versus oseltamivir as treatment for children with influenza virus infection. Antimicrob Agents Chemother. 2010;54:2575–2582.
   PubMed Web of Science ®Google Scholar
• Hayden F. Developing new antiviral agents for influenza treatment: what does the future hold? Clin Infect Dis. 2009;48:S3–S1.
   PubMed Web of Science ®Google Scholar
• Roche. Media release: Roche donates a further 2 million treatment courses of antiviral Tamiflu to the WHO for regional stockpiling (2006 Jan 17) [Internet]; [cited 2016-03-23]. Available from: www.roche.com/med-cor-2006-01-17.rtf
   Google Scholar
• Jack A. Roche steps up production of Tamiflu after virus scare. Financial Times. 13 May 2009; p. 17.
   Google Scholar
• Hoffmann-La Roche Inc. FDA Pediatric advisory committee briefing document for Tamiflu (2007) [Internet]; [cited 2016 Mar 23]. Available from: http://www.fda.gov/ohrms/dockets/ac/07/briefing/2007-4325b_02_15_Sponsor%20Background%20Package%20Roche.pdf.
   Google Scholar
• Glaxosmithkline FDA Pediatric Advisory Committee Meeting Relenza® (zanamivir) Inhalation Powder. Sponsor Backgrounder (Briefing Information) (2007-11-27) [Internet]; [cited 2016 Mar 23]. Available from: http://www.fda.gov/ohrms/dockets/ac/07/briefing/2007-4325b_02_16_Sponsor%20Background%20Package%20GSK.pdf.
   Google Scholar
• Ministry of Health, Labor and Welfare (MHLW): advisory panel for drug safety (held on 2014-10-29), usage review of neuraminidase inhibitors (in Japanese) [Internet]; [cited 2016 Mar 23]. Available from: http://www.mhlw.go.jp/file/05-Shingikai-11121000-Iyakushokuhinkyoku-Soumuka/0000063406.pdf.
   Google Scholar
• Bhatia A, Kast RE. How influenza's neuraminidase promotes virulence and creates localized lung mucosa immunodeficiency. Cell Mol Biol Lett. 2007;12:111–119.
   PubMed Web of Science ®Google Scholar
• Matrosovich MN, Matrosovich TY, Gray T, et al. Neuraminidase is important for the initiation of influenza virus infection in human airway epithelium. J Virol. 2004;78:12665–12667.
   PubMed Web of Science ®Google Scholar
• Moscona A. Neuraminidase inhibitors for influenza. N Engl J Med. 2005;353:1363–1373.
   PubMed Web of Science ®Google Scholar
• Ohuchi M, Asaoka N, Sakai T, et al. Roles of neuraminidase in the initial stage of influenza virus infection. Microbes Infect. 2006;8:1287–1293.
   PubMed Web of Science ®Google Scholar
• Liu C, Eichelberger MC, Compans RW, et al. Influenza type A virus neuraminidase does not play a role in viral entry, replication, assembly, or budding. J Virol. 1995;69:1099–1106.
   PubMed Web of Science ®Google Scholar
• Full prescription information of oseltamivir (revised in April 2010) [Internet]; [cited 2016-03-23]. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021087s057lbl.pdf
   Google Scholar
• Hayden FG, Treanor JJ, Fritz RS, et al. Use of the oral neuraminidase inhibitor oseltamivir in experimental human influenza: randomized controlled trials for prevention and treatment. JAMA. 1999;282:1240–1246.
   PubMed Web of Science ®Google Scholar
• Morimoto K, Nakakariya M, Shirasaka Y, et al. Oseltamivir (Tamiflu) efflux transport at the blood-brain barrier via P-glycoprotein. Drug Metab Dispos. 2008;36:6–9.
   PubMed Web of Science ®Google Scholar
• Ose A, Kusuhara H, Yamatsugu K, et al. P-glycoprotein restricts the penetration of oseltamivir across the blood-brain barrier. Drug Metab Dispos. 2008;36:427–434.
   PubMed Web of Science ®Google Scholar
• MHLW. Documents for the fifth 2007 advisory Panel on Drug Safety (held on 2007-12-25) (in Japanese) [Internet]; [cited 2016 Mar 23]. Available from: http://www.mhlw.go.jp/shingi/2007/12/s1225-7.html.
   Google Scholar
• Japanese SBA. Tamiflu capsule for treatment [Internet]; [cited 2016 Mar 23]. Available from: http://www.pmda.go.jp/drugs/2000/g001202/index.html.
   Google Scholar
• PMDA. Examination results by PMDA (Tamiflu capsule for treatment) [Internet]; [cited 2016 Mar 23]. Available from: http://www.pmda.go.jp/drugs/2000/g001202/70repo01.pdf.
   Google Scholar
• Hama R, Bennet C. The mechanisms of sudden-onset type adverse reactions to oseltamivir. Acta Neurologica Scandinavica (revised for publication).
   Google Scholar
• Sawabuchi T, Suzuki S, Iwase K, et al. Boost of mucosal secretory immunoglobulin A response by clarithromycin in paediatric influenza. Respirology. 2009;14:1173–1179.
   PubMed Web of Science ®Google Scholar
• Shinahara W, Takahashi E, Sawabuchi T, et al. Immunomodulator clarithromycin enhances mucosal and systemicimmune responses and reduces re-infection rate in pediatric patients with influenza treated with antiviral neuraminidase inhibitors: a retrospective analysis. PLoS One. 2013;8:e70060.
   PubMed Web of Science ®Google Scholar
• Takahashi E, Kataoka K, Fujii K, et al. Attenuation of inducible respiratory immune responses by oseltamivir treatment in mice infected with influenza A virus. Microbes Infect. 2010;12:778–783.
   PubMed Web of Science ®Google Scholar
• Takahashi E, Kataoka K, Indalao IL, et al. Oral clarithromycin enhances airway immunoglobulin A (IgA) immunity through induction of IgA class switching recombination and B-cell-activating factor of the tumor necrosis factor family molecule on mucosal dendritic cells in mice infected with influenza A virus. J Virol. 2012;86:10924–10934.
   PubMed Web of Science ®Google Scholar
• Cox RJ, Mykkeltvedt E, Sjursen H, et al. The effect of zanamivir treatment on the early immune response to influenza vaccination. Vaccine. 2001;19:4743–4749.
   PubMed Web of Science ®Google Scholar
• Fritz RS, Hayden FG, Calfee DP, et al. Nasal cytokine and chemokine responses in experimental influenza A virus infection: results of a placebo-controlled trial of intravenous zanamivir treatment. J Infect Dis. 1999;180:586–593.
   PubMed Web of Science ®Google Scholar
• Kopel E, Mandelboim M, Amitai Z, et al. Possible recurrent pandemic (H1N1) 2009 infection, Israel. Emerging Infect Dis. 2010;16:1321–1322.
   PubMed Web of Science ®Google Scholar
• Perez CM, Ferres M, Labarca JA. Pandemic (H1N1) 2009 reinfection, Chile. Emerging Infect Dis. 2010;16:156–157.
   PubMed Web of Science ®Google Scholar
• U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER). Guidance for Industry-Estimating the Maximum Safe Starting Dose in Initial Clinical Trials for Therapeutics in Adult Healthy Volunteers, 2005[Internet]; [cited 2016 Mar 23]. Available from: http://www.fda.gov/downloads/Drugs/Guidances/UCM078932.pdf.
   Google Scholar
• EMA. Marketing Authorization Application, Table of Contents–Volume 81. 1007–Brewster M. Ro 64–0802/002 (GS–4071) cardiovascular and respiratory evaluation in the anaesthetized dog following intravenous administrations (DHB08601).RR W–142974. 1999 (disclosed document from EMA).
   Google Scholar
• Hama R, Jones M, Jefferson T. Concerns about the randomization in the prophylaxis trials of oseltamivir (rapid response), 2015[Internet]; [cited 2016 Mar 23]. Available from: http://www.bmj.com/content/348/bmj.g2545/rr.
   Google Scholar
• The Dryad Digital Repository[Internet]; [cited 2016 Mar 23]. Available from: http://datadryad.org/resource/doi:10.5061/dryad.77471.
   Google Scholar
• Moore ML, Chi MH, Zhou W, et al. Cutting edge: oseltamivir decreases T cell GM1 expression and inhibits clearance of respiratory syncytial virus: potential role of endogenous sialidase in antiviral immunity. J Immunol. 2007;178:2651–2654.
   PubMed Web of Science ®Google Scholar
• Stamatos NM, Carubelli I, van de Vlekkert D, et al. LPS-induced cytokine production in human dendritic cells is regulated by sialidase activity. J Leukoc Biol. 2010;88:1227–1239.
   PubMed Web of Science ®Google Scholar
• Feng C, Zhang L, Almulki L, et al. Endogenous PMN sialidase activity exposes activation epitope on CD11b/CD18 which enhances its binding interaction with ICAM-1. J Leukoc Biol. 2011;90:313–321.
   PubMed Web of Science ®Google Scholar
• Marois I, Cloutier A, Garneau É, et al. The administration of oseltamivir results in reduced effector and memory CD8+ T cell responses to influenza and affects protective immunity. FASEB J. 2015;29:973–987.
   PubMed Web of Science ®Google Scholar
• Crain SM, Shen KF. Neuraminidase inhibitor, oseltamivir blocks GM1 ganglioside-regulated excitatory opioid receptor-mediated hyperalgesia, enhances opioid analgesia and attenuates tolerance in mice. Brain Res. 2004;995:260–266.
   PubMed Web of Science ®Google Scholar
• Mendel DB, Tai CY, Escarpe PA, et al. Oral administration of a prodrug of the influenza virus neuraminidase inhibitor GS 4071 protects mice and ferrets against influenza infection. Antimicrob Agents Chemother. 1998;42:640–646.
   PubMed Web of Science ®Google Scholar
• Onishi M, Kitano M, Taniguchi K, et al. Intravenous peramivir inhibits viral replication, and leads to bacterial clearance and prevention of mortality during murine bacterial co-infection caused by influenza A(H1N1)pdm09 virus and Streptococcus pneumoniae. Antiviral Res. 2015;117:52–59.
   PubMed Web of Science ®Google Scholar
• Tanaka A, Nakamura S, Seki M, et al. The effect of intravenous peramivir, compared with oral oseltamivir, on the outcome of post-influenza pneumococcal pneumonia in mice. Antivir Ther. 2015;20:11–19.
   PubMed Web of Science ®Google Scholar
• Kitano M, Kodama M, Itoh Y, et al. Efficacy of repeated intravenous injection of peramivir against influenza A (H1N1) 2009 virus infection in immunosuppressed mice. Antimicrob Agents Chemother. 2013;57:2286–2294.
   PubMed Web of Science ®Google Scholar
• Wong ZX, Jones JE, Anderson GP, et al. Oseltamivir treatment of mice before or after mild influenza infection reduced cellular and cytokine inflammation in the lung. Influenza Other Respir Viruses. 2011;5:343–350.
   PubMed Web of Science ®Google Scholar
• Hama R. Pharmacological toxicological clinical and epidemiological evidences of neuropsychiatric adverse reactions to oseltamivir and misleading analysis due to serious miscalculation in Japanese MHLW's 2006/07 epidemiological study report. (in Japanese). Jap J Clin Pharmacol Therap. 2009;40:13S–14S.
   Google Scholar
• Muraki K, Hatano N, Suzuki H, et al. Oseltamivir blocks human neuronal nicotinic acetylcholine receptor-mediated currents. Basic Clin Pharmacol Toxicol. 2014;116:87–95.
   PubMed Web of Science ®Google Scholar
• Izumi Y, Tokuda K, O'dell KA, et al. Neuroexcitatory actions of Tamiflu and its carboxylate metabolite. Neurosci Lett. 2007;426:54–58.
   PubMed Web of Science ®Google Scholar
• Izumi Y, Tokuda K, O'Dell K, et al. Synaptic and behavioral interactions of oseltamivir (Tamiflu) with neurostimulants. Hum Exp Toxicol. 2008;27:911–917.
   PubMed Web of Science ®Google Scholar
• Lindemann L, Jacobsen H, Schuhbauer D, et al. In vitro pharmacological selectivity profile of oseltamivir prodrug (Tamiflu) and active metabolite. Eur J Pharmacol. 2010;628:6–10.
   PubMed Web of Science ®Google Scholar
• Hiasa M, Isoda Y, Kishimoto Y, et al. Inhibition of MAO-A and stimulation of behavioural activities in mice by the inactive prodrug form of the anti-influenza agent oseltamivir. Br J Pharmacol. 2013;169:115–129.
   PubMed Web of Science ®Google Scholar
• Yamaguchi K, Hata K, Koseki K, et al. Evidence for mitochondrial localization of a novel human sialidase (NEU4). Biochem J. 2005;390:85–93.
   PubMed Web of Science ®Google Scholar
• Yamanami H, Shiozaki K, Wada T, et al. Down-regulation of sialidase NEU4 may contribute to invasive properties of human colon cancers. Cancer Sci. 2007;98:299–307.
   PubMed Web of Science ®Google Scholar
• Yoshizumi S, Suzuki S, Hirai M, et al. Increased hepatic expression of ganglioside-specific sialidase, NEU3, improves insulin sensitivity and glucose tolerance in mice. Metab Clin Exp. 2007;56:420–429.
   PubMed Web of Science ®Google Scholar
• Shelton MJ, Lovern M, Ng-Cashin J, et al. Zanamivir pharmacokinetics and pulmonary penetration into epithelial lining fluid following intravenous or oral inhaled administration to healthy adult subjects. Antimicrob Agents Chemother. 2011;55:5178–5184.
   PubMed Web of Science ®Google Scholar
• GlaxoSmithKline (then GlaxoWelcome) SBA (Relenza/zanamivir) 1999, (in Japanese) [Internet]; [cited 2016 Mar 23]. Available from: http://www.pmda.go.jp/drugs/1999/g991201/index.html.
   Google Scholar
• Daiichi-Sankyo. SBA(Inavir/laninamivir) 2010, (in Japanese) [Internet]; [cited 2015 May 27]. Available from: http://www.pmda.go.jp/drugs/2010/P201000050/index.html.
   Google Scholar
• Shionogi. SBA (Rapiacta/peramivir) 2010, (in Japanese) [Internet]; [cited 2016 Mar 23]. Available from: http://www.pmda.go.jp/drugs/2010/P201000001/index.html.
   Google Scholar
• Chengelis CP, Gad SC. Introduction. In: Gad SC, Chengelis CP, editors. Animal models in toxicology. New York: Marcel Dekker Inc; 1992. p. 1–20.
   Google Scholar
• Burrell GA. The use of mice and birds for detecting carbon monoxide after mine fire and explosion. Technical Paper 11, Washington (DC): Department of Interior, Beureau of Mines; 1912. p. 3–16.
   Google Scholar